Literature DB >> 9847302

Mutational analysis of the hydrophobic tail of the human immunodeficiency virus type 1 p6(Gag) protein produces a mutant that fails to package its envelope protein.

D E Ott1, E N Chertova, L K Busch, L V Coren, T D Gagliardi, D G Johnson.   

Abstract

The p6(Gag) protein of human immunodeficiency virus type 1 (HIV-1) is produced as the carboxyl-terminal sequence within the Gag polyprotein. The amino acid composition of this protein is high in hydrophilic and polar residues except for a patch of relatively hydrophobic amino acids found in the carboxyl-terminal 16 amino acids. Internal cleavage of p6(Gag) between Y36 and P37, apparently by the HIV-1 protease, removes this hydrophobic tail region from approximately 30% of the mature p6(Gag) proteins in HIV-1MN. To investigate the importance of this cleavage and the hydrophobic nature of this portion of p6(Gag), site-directed mutations were made at the minor protease cleavage site and within the hydrophobic tail. The results showed that all of the single-amino-acid-replacement mutants exhibited either reduced or undetectable cleavage at the site yet almost all were nearly as infectious as wild-type virus, demonstrating that processing at this site is not important for viral replication. However, one exception, Y36F, was 300-fold as infectious the wild type. In contrast to the single-substitution mutants, a virus with two substitutions in this region of p6(Gag), Y36S-L41P, could not infect susceptible cells. Protein analysis showed that while the processing of the Gag precursor was normal, the double mutant did not incorporate Env into virus particles. This mutant could be complemented with surface glycoproteins from vesicular stomatitis virus and murine leukemia virus, showing that the inability to incorporate Env was the lethal defect for the Y36S-L41P virus. However, this mutant was not rescued by an HIV-1 Env with a truncated gp41(TM) cytoplasmic domain, showing that it is phenotypically different from the previously described MA mutants that do not incorporate their full-length Env proteins. Cotransfection experiments with Y36S-L41P and wild-type proviral DNAs revealed that the mutant Gag dominantly blocked the incorporation of Env by wild-type Gag. These results show that the Y36S-L41P p6(Gag) mutation dramatically blocks the incorporation of HIV-1 Env, presumably acting late in assembly and early during budding.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9847302      PMCID: PMC103803     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences.

Authors:  L E Henderson; M A Bowers; R C Sowder; S A Serabyn; D G Johnson; J W Bess; L O Arthur; D K Bryant; C Fenselau
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

3.  Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release.

Authors:  H G Göttlinger; T Dorfman; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

4.  Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments.

Authors:  A H Kaplan; R Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

5.  The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions.

Authors:  X Yu; X Yuan; Z Matsuda; T H Lee; M Essex
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

6.  A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base.

Authors:  R A Poorman; A G Tomasselli; R L Heinrikson; F J Kézdy
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

7.  Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction.

Authors:  R M Horton; Z L Cai; S N Ho; L R Pease
Journal:  Biotechniques       Date:  1990-05       Impact factor: 1.993

8.  Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range.

Authors:  N R Landau; K A Page; D R Littman
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles.

Authors:  J Park; C D Morrow
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

10.  Phenotypes of murine leukemia virus-induced tumors: influence of 3' viral coding sequences.

Authors:  D E Ott; J Keller; K Sill; A Rein
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

View more
  28 in total

1.  Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain.

Authors:  M A Accola; B Strack; H G Göttlinger
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  A PLPPV sequence in the p8 region of Gag provides late domain function for mouse mammary tumor virus.

Authors:  Lori V Coren; Kunio Nagashima; David E Ott
Journal:  Virology       Date:  2019-07-19       Impact factor: 3.616

3.  Partial restoration of replication of simian immunodeficiency virus by point mutations in either the dimerization initiation site (DIS) or Gag region after deletion mutagenesis within the DIS.

Authors:  Y Guan; K Diallo; M Detorio; J B Whitney; C Liang; M A Wainberg
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Elimination of retroviral infectivity by N-ethylmaleimide with preservation of functional envelope glycoproteins.

Authors:  David R Morcock; James A Thomas; Tracy D Gagliardi; Robert J Gorelick; J David Roser; Elena N Chertova; Julian W Bess; David E Ott; Quentin J Sattentau; Ines Frank; Melissa Pope; Jeffrey D Lifson; Louis E Henderson; Bruce J Crise
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Functional roles of equine infectious anemia virus Gag p9 in viral budding and infection.

Authors:  C Chen; F Li; R C Montelaro
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction.

Authors:  R N Harty; M E Brown; J P McGettigan; G Wang; H R Jayakar; J M Huibregtse; M A Whitt; M J Schnell
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Mutations in human immunodeficiency virus type 1 nucleocapsid protein zinc fingers cause premature reverse transcription.

Authors:  James A Thomas; William J Bosche; Teresa L Shatzer; Donald G Johnson; Robert J Gorelick
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

8.  Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation.

Authors:  Aisha Nazli; Olivia Chan; Wendy N Dobson-Belaire; Michel Ouellet; Michel J Tremblay; Scott D Gray-Owen; A Larry Arsenault; Charu Kaushic
Journal:  PLoS Pathog       Date:  2010-04-08       Impact factor: 6.823

9.  Sequence of human immunodeficiency virus type 1 (HIV-1) Gag localization and oligomerization monitored with live confocal imaging of a replication-competent, fluorescently tagged HIV-1.

Authors:  Wolfgang Hübner; Ping Chen; Armando Del Portillo; Yuxin Liu; Ronald E Gordon; Benjamin K Chen
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

10.  Human immunodeficiency virus type 1-associated CD40 ligand transactivates B lymphocytes and promotes infection of CD4+ T cells.

Authors:  Geneviève Martin; Jocelyn Roy; Corinne Barat; Michel Ouellet; Caroline Gilbert; Michel J Tremblay
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.